Melanoma underreporting: Why does it happen, how big is the problem, and how do we fix it? - 24/04/13

Doi : 10.1016/j.jaad.2008.08.007

Myles Cockburn, PhD ^a,^b,^⁎ , Susan M. Swetter, MD ^c,^d, David Peng, MD ^e, Theresa H.M. Keegan, PhD ^f,^g, Dennis Deapen, DrPH ^a,^b, Christina A. Clarke, PhD ^f,^g
^a Department of Preventive Medicine, USC/Keck School of Medicine, Los Angeles, California
^b Los Angeles Cancer Surveillance Program, Los Angeles, California
^c Veterans Affairs Palo Alto Health Care System, Palo Alto, California
^d Stanford Comprehensive Cancer Center, Department of Dermatology/Pigmented Lesion and Melanoma Program, Palo Alto, California
^e Department of Dermatology, USC/Keck School of Medicine, Los Angeles, California
^f Northern California Cancer Center, Fremont, California
^g Stanford Comprehensive Cancer Center, Palo Alto, California

Reprint requests: Myles Cockburn, PhD, Los Angeles Cancer Surveillance Program, 1441 Eastlake Ave, MC9175, Los Angeles, CA 90089-9175.

Le texte complet de cet article est disponible en PDF.

Plan

Why are melanomas more likely to be underreported than other cancers?

What is the extent of the problem?

How do we fix the problem?

What can dermatologists and dermatopathologists do to make a difference?

The melanoma reporting checklist

How should melanomas be reported to your central registry?

At what point should I report an incident melanoma?

Conclusion

Data collection was supported by the SEER Rapid Response Surveillance Study program by a supplement to contracts N01-CN-65107 (NCCC) and N01-PC-35139 (USC) with the National Cancer Institute. Dr Cockburn was additionally supported by grant number U55/CCU921930-02 from the Centers for Disease Control and Prevention, NIEHS grant 5P30 ES07048, and by R01 CA121052. The collection of data used in this publication was supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. The ideas and opinions expressed herein are those of the author, and no endorsement by the State of California, Department of Health Services or Federal Government is intended or should be inferred. Dr Cockburn was funded in part by the Los Angeles Cancer Surveillance Program, and Drs Keegan and Clarke were funded in part by the Greater Bay Area Cancer Registry.

Conflicts of interest: None declared.